BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
301.12
+8.18 (2.79%)
At close: Mar 6, 2026, 4:00 PM EST
299.00
-2.12 (-0.70%)
After-hours: Mar 6, 2026, 7:40 PM EST
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for BeOne Medicines AG stock have an average target of 386.7, with a low estimate of 312 and a high estimate of 425. The average target predicts an increase of 28.42% from the current stock price of 301.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 8 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $417 → $425 | Buy | Maintains | $417 → $425 | +41.14% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $400 → $412 | Strong Buy | Maintains | $400 → $412 | +36.82% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $400 → $410 | Strong Buy | Maintains | $400 → $410 | +36.16% | Feb 27, 2026 |
| Barclays | Barclays | Buy Maintains $394 → $405 | Buy | Maintains | $394 → $405 | +34.50% | Feb 27, 2026 |
| Barclays | Barclays | Buy Maintains $385 → $394 | Buy | Maintains | $385 → $394 | +30.84% | Feb 4, 2026 |
Financial Forecast
Revenue This Year
46.49B
from 5.34B
Increased by 770.07%
Revenue Next Year
53.69B
from 46.49B
Increased by 15.48%
EPS This Year
3.39
from 2.47
Increased by 37.15%
EPS Next Year
4.85
from 3.39
Increased by 43.07%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.9B | 59.8B | |||
| Avg | 46.5B | 53.7B | |||
| Low | 44.4B | 50.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 815.9% | 28.7% | |||
| Avg | 770.1% | 15.5% | |||
| Low | 731.0% | 7.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.40 | 7.07 | |||
| Avg | 3.39 | 4.85 | |||
| Low | 2.56 | 2.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 77.9% | 108.6% | |||
| Avg | 37.1% | 43.1% | |||
| Low | 3.6% | -27.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.